FILTER

Refine your search with the following facets to narrow down your results.

5 Current news of InterMune

Roche purchases shares in tender offer for InterMune, Inc.

01-Oct-2014 - Roche and InterMune, Inc. announced that Roche’s wholly owned subsidiary Klee Acquisition Corporation has accepted for payment all shares validly tendered pursuant to its tender offer for all outstanding shares of common stock of InterMune, Inc. at USD 74.00 per share in cash. The tender offer ...

acquisitions Roche

NiKem Research Srl Enters Into Research Service Agreement with InterMune, Inc.

26-Jun-2007 - NiKem Research Srl, an Italian drug discovery service provider, announced that it has entered into a Research Service Agreement with InterMune, Inc. Under the terms of the agreement, NiKem will, in the next 12 months, use its medicinal chemistry and early ADMET/PK platform and expertise to ...

medicinal chemistry pulmonology

InterMune Closes Collaboration Agreement With Roche

06-Nov-2006 - InterMune, Inc. announced that on October 30, 2006, it successfully closed its Exclusive License and Collaboration Agreement with Roche for the exclusive worldwide development and commercialization of InterMune's hepatitis C virus (HCV) protease inhibitor program. The parties received notice of ...

hepatitis C milestones protease inhibitors +1

Combinature and InterMune collaborate on NMR fragment screening

08-Jun-2006 - Combinature Biopharm AG announced the partnership with InterMune involving its NMR-Fragment-Screening technology. Combinature will identify novel low molecular weight chemotypes, so-called fragments, to a target protein of InterMune. Moreover Combinature will determine the binding sites of such ...

Binding Site matter molecular weight

Targanta Acquires Late-Stage Antibiotic from InterMune

03-Jan-2006 - Targanta Therapeutics, a privately held biopharmaceutical company developing antibacterial drugs, announced that it has acquired the worldwide ownership interest in oritavancin, an antibiotic that has completed two Phase III clinical trials. Oritavancin, used to treat Gram-positive bacterial ...

bacteria bacterial infections catheters +6